Modality
Multispecific
MOA
HER2
Target
CD47
Pathway
Angiogenesis
Huntington'sAsthmaPsA
Development Pipeline
Preclinical
Feb 2021
→ Nov 2025
PreclinicalCurrent
NCT07176354
2,278 pts·Asthma
2021-02→2025-11·Terminated
2,278 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-015mo agoInterim· Asthma
2026-04-213w awayPDUFA· Asthma
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Preclinical
Termina…
Catalysts
Interim
2025-11-01 · 5mo ago
Asthma
PDUFA
2026-04-21 · 3w away
Asthma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07176354 | Preclinical | Asthma | Terminated | 2278 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 |